TrialNature medicine2024

Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial.

Lihua E Budde et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.